NV-AMBARELLA
2.1.2020 11:02:12 CET | Business Wire | Press release
Ambarella, Inc. (Nasdaq: AMBA), an artificial intelligence (AI) vision silicon company, today announced that Ambarella and Amazon Web Services, Inc. (AWS) customers can now use Amazon SageMaker Neo to train machine learning (ML) models once and run them on any device equipped with an Ambarella CVflow®-powered AI vision system on chip (SoC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200102005052/en/
Until now, developers had to manually optimize ML models for devices based on Ambarella AI vision SoCs. This step could add considerable delays and errors to the application development process. Ambarella and AWS collaborated to simplify the process by integrating the Ambarella toolchain with the Amazon SageMaker Neo cloud service. Now, developers can simply bring their trained models to Amazon SageMaker Neo and automatically optimize the model for Ambarella CVflow-powered SoCs.
Customers can build an ML model using MXNet, TensorFlow, PyTorch, or XGBoost and train the model using Amazon SageMaker in the cloud or on their local machine. Then, they can upload the model to their AWS account and use Amazon SageMaker Neo to optimize the model for Ambarella SoCs. They can choose CV25, CV22, or CV2 as the compilation target. Amazon SageMaker Neo compiles the trained model into an executable that is optimized for Ambarella’s CVflow neural network accelerator. The compiler applies a series of optimizations that can make the model run up to 2x faster on the Ambarella SoC. Customers can download the compiled model and deploy it to their fleet of Ambarella-equipped devices. The optimized model runs in the Amazon SageMaker Neo runtime purpose-built for Ambarella SoCs and available for the Ambarella SDK. The Amazon SageMaker Neo runtime occupies less than 10x the disk and memory footprint of TensorFlow, MXNet, or PyTorch, making it much more efficient to deploy ML models on connected cameras.
“Ambarella is in mass production today with CVflow AI vision processors for the home monitoring, enterprise video security, and automotive markets,” said Chris Day, vice president of marketing and business development for Ambarella. “The ability to select an Ambarella SoC and compile a trained ML model with a single click is a powerful tool that makes it possible for our customers to rapidly bring the next generation of AI-enabled products to market.”
Manufactured using an advanced 10-nanometer process, Ambarella’s CVflow SoC family enables the design of compact, high-performance vision systems with ultra-low power operation. For example, the Ambarella CV22 CVflow SoC delivers computer vision processing at full 4K or 8-megapixel resolution at 30 frames per second (fps), while its image signal processor (ISP) provides outstanding imaging in low light conditions and high-contrast scenes, further enhancing the computer vision capabilities of the chip. The CV22 also includes a suite of advanced security features to protect against hacking including secure boot, TrustZone®, I/O virtualization, and support for online upgrades over the air (OTA).
“AWS has the broadest and deepest set of ML and AI services focused on solving some of the toughest challenges facing developers. Amazon SageMaker is a fully managed service that provides every developer and data scientist with the ability to build, train, and deploy machine learning models quickly,” said Bratin Saha, vice president, Machine Learning & Engines, Amazon Web Services, Inc. “We’re excited that VIVOTEK is using SageMaker Neo to simplify the deployment of ML models at the edge on Ambarella CVflow-powered IP cameras.”
VIVOTEK (TWSE:3454), a leading global IP surveillance solution provider and customer of both Ambarella and AWS, will now be able to deploy advanced ML capabilities to a new camera product line—powered by the Ambarella CV series SoCs—more quickly using Amazon SageMaker Neo. Dr. Steve Ma, vice president of engineering, Brand Business Division, VIVOTEK INC. said, “We’re excited that we will be able to explore training and deploying the machine learning models increasingly demanded by our customers to our future Ambarella CV series powered cameras with Amazon SageMaker Neo, potentially saving us months of hand-tuning the individual models for optimal performance on the edge. Using Amazon SageMaker Neo ensures that our IP camera solutions are fully able to leverage the market-leading computer vision capabilities of the Ambarella SoC.”
Ambarella will demonstrate the integration with Amazon SageMaker Neo during CES 2020 to select customers and partners.
The URL for this news release and the related image: https://www.ambarella.com/news-events/
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving, and robotic applications. Ambarella’s low-power system on chips (SoCs) offer high-resolution video compression, advanced image processing, and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications and pricing at any time without notice. ©2020 Ambarella. All rights reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200102005052/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom